infection remains the same. Our results are consistent with other studies from various parts of the world. 1, 2, 5 Regarding increased prevalence of co-infection with C. trachomatis and Ureaplasma spp., recent studies have demonstrated certain survival advantages for C. trachomatis probably through direct or indirect supply of tryptophan to overcome its intracellular depletion by interferon γ exposure, although the exact mechanism remains obscure. 6 Compared to our previous studies, which had only biovar 1 isolates, our present study showed a predominant shifting trend towards biovar 2. U. urealyticum (biovar 2) is more significantly associated with nongonococcal urethritis. U. parvum is more commonly found in asymptomatic healthy subjects.
Limitations of our study include its retrospective design and collection of data from a single center only. Also, we were unable to perform antimicrobial susceptibility testing of the Ureaplasma isolates due to financial constraints.
To conclude, this initial data mirrors the upward trend of genital mycoplasma infections, asbeing observed worldwide. Our analysis supports the increasing prevalence of genital mycoplasmas, especially Ureaplasma spp. as etiologic agents in patients with genital tract diseases. More detailed studies in India could contribute to a better understanding of the epidemiology and pathogenesis and facilitate the development of better strategies for their treatment and prevention.
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Anti-pruritic efficacies of doxycycline and erythromycin in the treatment of acne vulgaris: A randomized single-blinded pilot study
Sir, Pruritus is a significant symptom that is frequently experienced by patients with acne vulgaris and contributes significantly to patients' morbidity. 1, 2 In our clinical experience, pruritus in acne vulgaris can be effectively reduced with systemic antibiotics, such as doxycycline and erythromycin, which are commonly used as first-line systemic acne medications. However, it is not known if this effect results from a decrease in inflammation alone or if there are additional anti-pruritic effects mediated by the antibiotics.
A study on human keratinocytes demonstrated that tetracycline attenuates the protease-activated receptor 2 interleukin-8 axis in the modulation of proinflammatory responses. 3 This effect was not observed in the macrolides, including erythromycin and clarithromycin. 4 Because protease-activated receptor 2 has been shown by multiple studies to be an important itch receptor, doxycycline may possibly have a greater efficacy in relieving itch through the inhibition of protease-activated receptor 2, as compared to erythromycin.
The aim of this randomized single-blinded pilot trial was to evaluate the anti-pruritic efficacies of doxycycline and erythromycin in the treatment of acne vulgaris. Approval for the study was obtained from the National Healthcare Group Ethics Review Board and Health Sciences Authority, Singapore.
Patients with mild-to-moderate acne based on the Comprehensive Acne Severity Scale [Figures 1 and 2] and associated itch intensity of more than 2 on a 10-point numerical scale were recruited from the dermatology clinics at the National Skin Centre in Singapore. 5 Subjects were randomized to receive either oral doxycycline 100 mg daily or erythromycin 500 mg b.d. for 6 weeks. All subjects were instructed to stop the application of any topical agents during this period and to use the same type of mild cleanser (QV wash®) for facial washing up to a maximum of three times a day. At baseline and 6 weeks after treatment, an itch questionnaire was administered; 6 which included the average itch intensity over the prior 1 week on a 10-point numerical scale, frequency of itch (graded 1-7, ranging from 1 episode a month to more than 10 episodes daily) and itch quality-of-life assessment (16 questions, each graded 1-6 ranging from not affected to severely affected, giving a total score of 16-96). The severity of acne was also graded by a dermatologist blinded to the treatment arm (graded 0-5 on the Comprehensive Acne Severity Scale [ Figure 3 ], from clear to very severe) at baseline and at 6 weeks. Analyses were performed on a per-protocol basis using the paired t-test (for within-group comparisons) and two-sample t-test (for between-groups comparisons).
Thirty-six subjects were recruited, of whom 29 completed the study and 7 were lost to follow-up. Of the 29 subjects, 14 received erythromycin, while 15 received doxycycline. Both groups had comparable baseline characteristics [ Table 1 ]. Grading of acne severity [ Table 2 ] significantly improved in both groups (P < 0.01), and there was no significant difference between the two treatment arms (P = 0.29). Subjects in the doxycycline group experienced a significant reduction in itch intensity scores at 6 weeks (P = 0.03) and this remained significant after adjusting for improvement in acne grading (P = 0.02). The reduction in itch intensity scores was not statistically significant in the erythromycin group (P = 0.11).
Comparing the efficacies of doxycycline and erythromycin in reducing itch intensity scores, the difference was not statistically significant (P = 0.42). The itch quality-of-life scores were significantly better in both groups (P = 0.03), but the frequency of itch was not much different.
We were unable to find any previous reports of the anti-pruritic efficacies of systemic antibiotics in the treatment of acne. Doxycycline was found to significantly reduce pruritus in acne vulgaris and we postulate that in addition to a reduction in inflammation, attenuation of the protease-activated receptor 2 interleukin-8 pathway may contribute to this effect. A limitation of this study is the relatively high dropout rate (19%). Sample size is very small. Other factors like age of the patient, other comorbidities and general skin condition have not been taken into consideration.
In conclusion, our results revealed that doxycycline effectively reduces itch intensity in pruritic acne and this effect was independent of improvements in acne severity. Doxycycline may serve as a good antibiotic option for patients who experience itch in their acne lesions. These questions concern the skin condition which has bothered you the most during the past week. On a scale of 0-6 (0 being never and 6 being frequent), during the past week, how often have you been bothered by:
Your skin condition itching Your skin condition burning or stinging
Your skin condition hurting
Your skin condition being irritated
The persistence/reoccurrence of your skin condition Worry about your skin condition (e.g., that it will spread, get worse, scar, unpredictable etc.)
The appearance of your skin condition 
